CLINICAL STUDIES
ONGOING CLINICAL STUDIES – CANINE AND FELINE SPECIES
Dogs suffering from Osteosarcomas / Bone surgery (fractures, arthrodesis, TTA) - Recruitment in progress
20-THV-06
Osteosarcomas / Bone surgery
Objective
To assess the efficacy and safety of an innovative Medical Device, an injectable phosphocalcic cement, in the treatment of osteosarcomas or in the case of bone surgeries such as fracture repairs, arthrodesis, Tibial Tuberosity Advancement (TTA) procedures following a rupture of the cruciate ligament.
Main clinical end-points
To evaluate the effectiveness of the Medical Device on the preservation of the function of the affected limb.
To evaluate the analgesic effect and the tolerance of the Medical Device.
Study Duration
Surgery + 8-week follow-up visit for bone surgeries
Surgery + follow-up visits up to 6 months for osteosarcomas
Clinical Evaluation
Clinic (clinical examination, questionnaires), x-rays of the bone
Dogs with spontaneous, primary, intracerebral high-grade glioma - Recruitment in progress
18-ONCO-01 (part A)
Glioma
Objectives
To assess the efficacy and safety of Investigational Product in dogs with spontaneous, primary, intracerebral high-grade glioma
To determine pharmacokinetics parameters of Investigational Product
Main criteria
Intracerebral high-grade glioma suspected based on brain MRI
Subcortical, intraparenchymal and rostrotentorially located tumor
Maximum 14 cm between entries of both ear canals
No uncontrolled seizures
Administration
Single, intratumoral infusion using convection-enhanced delivery technique
Treatment duration
Single administration + follow up for 2 months – 5 visits
Evaluation
Regular clinical and biological exam
Brain MRI
Financial coverage
Full financial coverage of the treatment, consultations, clinical/biological exams and medical imaging planned in the protocol
Dogs suffering from Osteosarcomas / Bone surgery (fracture repairs, arthrodesis, TTA) - Recruitment in progress
20-THV-06
Osteosarcomas / Bone surgery
Objective
To assess the efficacy and safety of an innovative Medical Device, an injectable phosphocalcic cement, in the treatment of osteosarcomas or in the case of bone surgeries such as fracture repairs, arthrodesis, Tibial Tuberosity Advancement (TTA) procedures following a rupture of the cruciate ligament.
Main clinical end-points
To evaluate the effectiveness of the Medical Device on the preservation of the function of the affected limb.
To evaluate the analgesic effect and the tolerance of the Medical Device.
Study Duration
Surgery + 8-week follow-up visit for bone surgeries
Surgery + follow-up visits up to 6 months for osteosarcomas
Clinical Evaluation
Clinic (clinical examination, questionnaires), x-rays of the bone
Dogs with osteopenia risk - Recruitment in progress
Titre : 19-OSP-06*
Risk of osteopenia
Objectif
To assess the tolerance and efficacy of home-taken insect meal in dogs with osteopenia risk
Critères principaux
sterilization of more than one year, untreated Cushing syndrome or long-term corticotherapy
Administration
Per os
Durée du traitement
90 days
Prise en charge
Consultation, treatment, studies performed during the study
Clinics : Oncovet (France, near LILLE) & 3 in Belgium
Dogs with degenerative mitral valve disease - Recruitment in progress
18-CARD-03
Mitral Degenerative Valve Disease
Objective
To assess the efficacy of a new veterinary medicinal product for dogs with degenerative mitral valve disease at preclinical stage B1 (ACVIM consensus)
Main criteria
Small breed dogs in the early phase of the disease, therefore presenting a heart murmur (intensity ≥ 3/6) without any symptoms
Administration
Home treatment – orally – twice a day
Treatment duration
Minimum 16-month follow-up, with 1 visit every 4 months
Clinical follow-up
Clinical, echocardiographic, radiographic and laboratory assessment every 4 months
Financial coverage
Full coverage of the study treatment, all consultations, examinations and analyzes during the study period
Cats suffering from anemia with chronic kidney disease - Recruitment in progress
18-INTM-05*
Cats with anemia associated with Chronic Kidney Disease
Objective
To evaluate the effectiveness of a new veterinary medicinal product to manage anemia in cats associated with chronic kidney disease
Main criteria
Non-regenerative anemia and Chronic kidney disease
Treatment modalities
Treatment at home, per os
Follow-up every week during the first month (every two weeks after during 20 weeks)
Treatment duration
24 weeks
Evaluation
Regular clinical & biological assessment
Financial coverage
Full financial coverage of the treatment, all consultations with clinical & biological exams planned in the protocol
Additional compensation for the owner : discount up to 100 € (exclusive VAT) for feline diet or concomitant treatments taken during the participation to the protocol
CONTACTS
OCR – Parc Eurasanté, Lille Métropole – 80 Rue du Docteur Yersin, 59120 LOOS – FRANCE
+33 (0)6 63 51 39 71 – mdubruque@oncovet-clinical-research.com – www.oncovet-clinical-research.com
YOU ARE A VET?
WHY OFFER YOUR CLIENTS TO
PARTICIPATE IN A CLINICAL STUDY?
Participating in clinical trials represents an opportunity of scientific publications for veterinary scientific community
in the field of comparative pathology, an international growing sector.
You give access to your clients to an innovative treatment which is not yet available on the market
You give free access to care for your clients
You offer a therapeutic alternative in case of failure of standard treatments
You take part in the research development in human and veterinary health
You offer a solution for cases without therapeutic options (unresectable malignant tumors)
